A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.-MedSci.cn

A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

Burris, HA; Patel, MR; Cho, DC; Clarke, JM; Gutierrez, M; Zaks, TZ; Frederick, J; Hopson, K; Mody, K; Binanti-Berube, A; Robert-Tissot, C; Goldstein, B; Breton, B; Sun, J; Zhong, S; Pruitt, SK; Keating, K; Meehan, RS; Gainor, JF

JOURNAL OF CLINICAL ONCOLOGY, 2019; 37 (15):

科室
- - 订阅+
  - 更多科室
工具
服务